[go: up one dir, main page]

CO2022014111A2 - Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 - Google Patents

Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4

Info

Publication number
CO2022014111A2
CO2022014111A2 CONC2022/0014111A CO2022014111A CO2022014111A2 CO 2022014111 A2 CO2022014111 A2 CO 2022014111A2 CO 2022014111 A CO2022014111 A CO 2022014111A CO 2022014111 A2 CO2022014111 A2 CO 2022014111A2
Authority
CO
Colombia
Prior art keywords
benzylpyridin
heterocyclylalkyl
heterocyclyl
amine derivatives
sstr4
Prior art date
Application number
CONC2022/0014111A
Other languages
English (en)
Inventor
Zacharia Cheruvallath
Jason Green
Kristin Schleicher
Huikai Sun
Mingnam Tang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2022014111A2 publication Critical patent/CO2022014111A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula 1, , y sales farmacéuticamente aceptables de estos, en donde n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 y X12 se definen en la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de la Fórmula 1, a composiciones farmacéuticas que los contienen, y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con SSTR4.
CONC2022/0014111A 2020-03-31 2022-09-30 Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 CO2022014111A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002623P 2020-03-31 2020-03-31
PCT/US2021/025225 WO2021202775A1 (en) 2020-03-31 2021-03-31 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists

Publications (1)

Publication Number Publication Date
CO2022014111A2 true CO2022014111A2 (es) 2022-12-30

Family

ID=75660334

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014111A CO2022014111A2 (es) 2020-03-31 2022-09-30 Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4

Country Status (17)

Country Link
US (1) US12428403B2 (es)
EP (1) EP4126849A1 (es)
JP (1) JP7734147B2 (es)
KR (1) KR20220161437A (es)
CN (1) CN115485273B (es)
AR (1) AR121682A1 (es)
AU (1) AU2021249109A1 (es)
BR (1) BR112022019583A2 (es)
CA (1) CA3178347A1 (es)
CL (1) CL2022002692A1 (es)
CO (1) CO2022014111A2 (es)
EC (1) ECSP22082219A (es)
IL (1) IL296602A (es)
MX (1) MX2022012225A (es)
PE (1) PE20230740A1 (es)
TW (1) TW202204342A (es)
WO (1) WO2021202775A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
RU2403250C2 (ru) 2005-06-02 2010-11-10 Ф.Хоффманн-Ля Рош Аг Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
US7674804B2 (en) 2006-06-29 2010-03-09 Hoffmann-La Roche Inc. Pyrimidine and quinazoline derivatives as SST5 modulators
US7754744B2 (en) 2006-08-15 2010-07-13 Hoffmann-La Roche Inc. Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists
CN102791703B (zh) 2009-10-30 2014-07-09 詹森药业有限公司 用作δ阿片类受体调节剂的吡嗪
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
IL269241B (en) 2017-03-16 2022-09-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4

Also Published As

Publication number Publication date
CL2022002692A1 (es) 2023-06-16
JP2023520006A (ja) 2023-05-15
IL296602A (en) 2022-11-01
CA3178347A1 (en) 2021-10-07
WO2021202775A1 (en) 2021-10-07
EP4126849A1 (en) 2023-02-08
AU2021249109A1 (en) 2022-10-20
CN115485273A (zh) 2022-12-16
JP7734147B2 (ja) 2025-09-04
PE20230740A1 (es) 2023-05-03
AR121682A1 (es) 2022-06-29
BR112022019583A2 (pt) 2022-12-06
CN115485273B (zh) 2024-08-13
ECSP22082219A (es) 2022-12-30
KR20220161437A (ko) 2022-12-06
US12428403B2 (en) 2025-09-30
TW202204342A (zh) 2022-02-01
MX2022012225A (es) 2022-10-27
US20230192659A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CL2020002257A1 (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CL2020002562A1 (es) (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO2022014423A2 (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
AR127050A1 (es) Compuestos espirocíclicos
CO2022014111A2 (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
CR20190379A (es) Moduladores del receptor de estrógeno
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2024014680A2 (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
CO2024017138A2 (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
MX2022002839A (es) Nuevo compuesto heterocíclico aromático tricíclico, método de preparación del mismo, composición farmacéutica y aplicación del mismo.
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2025011205A2 (es) Derivados de 1-amino-4-fenilftalazina útiles para el tratamiento de enfermedades neurodegenerativas
AR054109A1 (es) Derivados de 2-metil-4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de la infertilidad
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal
ECSP972047A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos